Lilly to test combinations with Merck, Bristol-Myers’ cancer drugs
(Reuters) – Eli Lilly & Co signed two separate deals with Merck & Co Inc and Bristol-Myers Squibb Co to test combinations of its cancer treatments with two recently approved therapies that belong to a promising new class of drugs. Lilly will test its treatments – approved and experimental – in combination with PD-1 inhibitors Keytruda and Opdivo. The treatments are designed to help the body’s own immune system fight cancer by blocking a protein called Programmed Death receptor (PD-1). Bristol-Myers’ Opdivo was approved by the U.S. Food and Drugs Administration on Dec. 22. …
Go to Source